Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Investment Securities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Gains from Investment Securities for 7 consecutive years, with $11.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 8.14% to $11.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.3 million, a 159.44% increase, with the full-year FY2025 number at $11.3 million, up 17.81% from a year prior.
  • Gains from Investment Securities was $11.3 million for Q4 2025 at Beam Therapeutics, up from -$454000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $23.4 million in Q1 2021 to a low of -$23.2 million in Q2 2021.
  • A 5-year average of $1.4 million and a median of $426500.0 in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 17337.31% in 2021; the steepest drop was 1414.18% in 2021.
  • Beam Therapeutics' Gains from Investment Securities stood at -$23.2 million in 2021, then rose by 11.08% to -$20.6 million in 2022, then surged by 44.86% to -$11.4 million in 2023, then skyrocketed by 208.44% to $12.3 million in 2024, then decreased by 8.14% to $11.3 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Gains from Investment Securities are $11.3 million (Q4 2025), -$454000.0 (Q3 2025), and $28000.0 (Q2 2025).